Pregabalin

Generic Name
Pregabalin
Brand Names
Lyrica, Pregabalin Accord, Pregabalin Pfizer, Pregabalin Sandoz, Pregabalin Mylan, Pregabalin Zentiva
Drug Type
Small Molecule
Chemical Formula
C8H17NO2
CAS Number
148553-50-8
Unique Ingredient Identifier
55JG375S6M
Background

Pregabalin is structurally similar to gamma-aminobutyric acid (GABA) - an inhibitory neurotransmitter. It may be used to manage neuropathic pain, postherpetic neuralgia, and fibromyalgia among other conditions. Although as per the FDA Label the mechanism of action has not been definitively defined, there is evidence that pregabalin exerts its effects by bind...

Indication

Pregabalin is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, neuropathic pain associated with spinal cord injury, and as adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older.

Associated Conditions
Diabetic Peripheral Neuropathic Pain (DPN), Epilepsies, Fibromyalgia, Generalized Anxiety Disorder, Neuropathic Pain, Partial-Onset Seizures, Peripheral Neuropathic Pain, Peripheral neuropathy, Postherpetic Neuralgia
Associated Therapies
-
Clinical Trials
Related News

Evaluation of Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.

Phase 3
Completed
Conditions
Seizure Disorder, Partial
First Posted Date
2005-09-08
Last Posted Date
2015-03-05
Lead Sponsor
Pfizer
Target Recruit Count
337
Registration Number
NCT00150293
Locations

Pfizer Investigational Site

Pregabalin In Partial Seizures Extension Study

Phase 3
Completed
Conditions
Seizures
Interventions
Drug: Pregabalin
First Posted Date
2005-09-02
Last Posted Date
2021-01-28
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
227
Registration Number
NCT00143130
Locations
🇨🇭

Pfizer Investigational Site, Zurich, Switzerland

Pregabalin Open-Label Extension Trial in Patients With Partial Seizures

First Posted Date
2005-09-02
Last Posted Date
2006-07-24
Lead Sponsor
Pfizer
Target Recruit Count
300
Registration Number
NCT00143143
Locations

Pfizer Investigational Site

Pregabalin vs Placebo in Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

Phase 3
Completed
Conditions
Diabetic Neuropathies
First Posted Date
2005-09-02
Last Posted Date
2021-01-22
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
450
Registration Number
NCT00143156
Locations
🇵🇷

Pfizer Investigational Site, Ponce, Puerto Rico

The Effects of GABA Enhancing Medications on Individuals Addicted to Cocaine - 3

Not Applicable
Terminated
Conditions
Cocaine-Related Disorders
Cocaine Abuse
Interventions
Drug: placebo
Drug: Pregabalin
First Posted Date
2005-09-02
Last Posted Date
2015-07-08
Lead Sponsor
Yale University
Target Recruit Count
72
Registration Number
NCT00142883
Locations
🇺🇸

VA Connecticut Healthcare System, West Haven, Connecticut, United States

Pregabalin Peripheral Neuropathic Pain Study

First Posted Date
2005-09-01
Last Posted Date
2021-02-09
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
241
Registration Number
NCT00141219
Locations
🇰🇷

Pfizer Investigational Site, Seoul, Korea, Republic of

Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Chronic Neuropathic Pain.

Phase 3
Completed
Conditions
Pain
First Posted Date
2005-09-01
Last Posted Date
2007-01-01
Lead Sponsor
Pfizer
Target Recruit Count
325
Registration Number
NCT00141362

To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.

Phase 2
Completed
Conditions
Epilepsy, Partial
First Posted Date
2005-09-01
Last Posted Date
2007-01-01
Lead Sponsor
Pfizer
Target Recruit Count
82
Registration Number
NCT00141414
Locations
🇩🇪

Pfizer Investigational Site, Bonn, Germany

To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.

Phase 3
Completed
Conditions
Seizure Disorder, Partial
First Posted Date
2005-09-01
Last Posted Date
2007-01-01
Lead Sponsor
Pfizer
Target Recruit Count
325
Registration Number
NCT00141245
Locations
🇬🇧

Pfizer Investigational Site, York, United Kingdom

To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.

Phase 3
Completed
Conditions
Seizure Disorder, Partial
First Posted Date
2005-09-01
Last Posted Date
2007-01-01
Lead Sponsor
Pfizer
Target Recruit Count
750
Registration Number
NCT00141336
Locations
🇨🇦

Pfizer Investigational Site, Toronto, Ontario, Canada

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy